Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review covers clinical studies on using homoeopathy to treat PCOS and concludes that further rigorous research is necessary to substantiate its effectiveness.

In this study, germacrone from Curcuma aeruginosa showed anti-androgenic effects by inhibiting 5α-reductase, suggesting its potential as a lead compound for treating androgen-dependent disorders.

This study found that ethanol extract of Tubtim Chumphae rice bran downregulates SRD5A gene expression, similarly to finasteride, suggesting potential use as an anti-hair loss product.

This study found that antiandrogenic compounds in Curcuma aeruginosa, including germacrone, degrade rapidly at high temperatures but are more stable when solubilized in PEG-40.

This study suggests that the activation of box A in mesenchymal cell models may enhance stem cell properties, increasing the expression of stemness markers like OCT4, NANOG, and SOX2.

This study examined the stability of two 5α-reductase inhibitors in Tectona grandis extracts, finding that they are more stable in acidic environments and degrade rapidly under heat and light unless protected, suggesting the need for careful storage when developing anti-hair loss medications.

This study found that gels containing glycyrrhizic acid and aqueous Glycyrrhiza glabra extract significantly reduced underarm hair growth in terms of area, thickness, length, and number compared to their gel bases.

This article reviews knowledge-sharing efforts in pharmaceutical sciences at the University of Sorocaba, highlighting global collaboration on rational medicine use, without reporting new study results.

This article discusses the Graduate Program in Pharmaceutical Sciences at the University of Sorocaba and emphasizes collaborating internationally to improve health policies and practices but reports no new research findings.

This review covers nonsteroid-based therapies for alopecia areata, finding potential in PRP, UVR, and laser treatments, but highlights a lack of high-quality evidence for their efficacy.

This source reports that a network meta-analysis found oral baricitinib and ruxolitinib to be effective and safe for treating alopecia areata, significantly improving response rates over placebos and showing fewer adverse effects than steroid treatments, though precise dosing needs further study.

A new test helps find drugs to treat head and neck cancer by targeting c-Rel.

In this study, researchers used NIR-II fluorescence imaging to track the survival and migration of EPI-NCSCs in rat models, finding that these stem cells aided in repairing facial nerve defects when applied via acellular nerve allografts.

This phase I study reported that ETC-159, targeting Wnt signalling, showed tolerable safety profiles at doses that inhibit its pathway, though bone turnover markers increased, warranting early and regular monitoring. No tumor responses were observed, but two patients achieved stable disease for several cycles.

This article reviews the multifunctional roles of calreticulin outside the ER and highlights its impact on wound healing in animal models, but reports no new clinical results.

This study highlights that variations in clinical outcome reporting can undermine the validation of NTCP models for RIA, stressing the need for a standardized and objective scoring system.

In this study, induction nab-paclitaxel plus cisplatin, combined with nimotuzumab and IMRT, followed by S-1 adjuvant chemotherapy, showed excellent survival benefits with tolerable toxicities for stage N3 nasopharyngeal carcinoma patients.

This study observed that topically applied RTA 408 reduced the severity of radiation-induced dermatitis in mice, with the highest dose significantly reducing and alleviating skin damage and associated inflammation.

The researchers reported two brothers with a new variant of X-linked trichothiodystrophy associated with an RNF113A gene mutation, highlighting features such as intellectual disability and growth failure, but without previously reported endocrinological or genital abnormalities, underlining the importance of genetic counseling for such variants.

This study reported that patients with alopecia areata treated with ritlecitinib in a real-life setting had a higher rate of positive response on the Severity of Alopecia Tool score compared to those in the ALLEGRO trial.

This study suggests that the NCSTN knockout mouse could serve as an HS animal model, with tamoxifen potentially used for gene deletion in mice.

In this phase I study, CT-707, a new ALK inhibitor, showed a 77% response rate among Chinese patients with advanced ALK-rearranged non-small cell lung cancer, suggesting clinical effectiveness despite some adverse events like diarrhea and liver enzyme elevation.

In this real-world study, 27% of alopecia areata patients treated with ritlecitinib achieved a target SALT score, a result consistent with clinical trial findings, highlighting the value of patient-reported outcomes in understanding treatment impact beyond traditional measures.

This review discusses the structure, expression, regulation, and potential functions of the nuclear receptor coactivator NcoA4 in cancerous and non-cancerous pathologies, but reports no new results.

In this phase 2a study of adults with alopecia areata, researchers observed that ritlecitinib treatment did not result in significant differences in brainstem auditory evoked potential changes or axonal swelling compared to placebo, suggesting the dog toxicity findings may not be clinically relevant in humans.

This audit of ritlecitinib prescribing for severe alopecia areata found that regional practices largely followed national guidelines but highlighted the need for better psychological assessments and more consistent use of SALT scoring to inform treatment continuation decisions after 36 weeks.

This study reports that the nuclear receptor co-repressor 1 (NCoR1) inhibits cardiac hypertrophy by stabilizing the MEF2 and class II HDACs complex, potentially offering a target for new therapies.

In this prospective study, ritlecitinib effectively reduced hair loss in patients with severe alopecia areata, with 43.3% of participants achieving a 20 or lower SALT score by week 24, and showed a good midterm safety profile.

This review discusses the calcineurin/NFAT pathway's role in cutaneous squamous cell carcinoma, noting its involvement in tumor development, skin cell behavior, and the tumor microenvironment; it reports no new results.